Pseudomonas Infections clinical trials
The registry lists 136 studies for Pseudomonas Infections across more than 10 countries. 27 are recruiting or about to start. 42 of them are mainly about Pseudomonas Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Pseudomonas Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Gilead Sciences (11) · Sohag University (4) · Novartis Pharmaceuticals (4) · Humanigen, Inc. (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Assistance Publique - Hôpitaux de Paris (3) · The Hospital for Sick Children (2) · Polyphor Ltd. (2)
What is being tested here
Drugs under test in Pseudomonas Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ceftazidime | 1 | 0 | 5 |
| Ceftolozane | 1 | 0 | 3 |
| MP-101 | 1 | 0 | 1 |
| Inosine Monophosphate | 1 | 0 | 1 |
| Pseudomonas aeruginosa | 1 | 0 | 1 |
| Tobramycin | 0 | 4 | 9 |
| Aztreonam | 0 | 2 | 5 |
| Amikacin | 0 | 1 | 4 |
| Ciprofloxacin | 0 | 0 | 3 |
| Meropenem | 0 | 0 | 3 |
Drug classes tested here Beta-lactamase inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8
- Nov 2026Early Optimization of Ceftazidime Regimen in Critical Care · Centre Hospitalier Universitaire de Saint Etienne
- Dec 2026MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia · MicrobiotiX Co., Ltd
- Jan 2027Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa · Centre Hospitalier Régional d'Orléans
- May 2027Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial · Johns Hopkins University
- Jun 2027Remote Sputum Collection in Cystic Fibrosis · University of Pennsylvania
- Jul 2027Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients · Sizhou Feng
- Sep 2027Microbiological Screening Of Malignant Otitis Externa Patients Presenting at Sohag University Hospitals · Sohag University
- Sep 2027Further MT for Antibiotic-Resistant Bacterial Colonization · Emory University
Who these studies take
Of the 20 Pseudomonas Infections studies recruiting now, 11 (55%) set no upper age limit and 2 (10%) stop at 75 or younger. 4 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (15%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (15%) | 3 (15%) |
| 18 | 19 (95%) | 19 (95%) |
| 30 | 20 (100%) | 20 (100%) |
| 40 | 20 (100%) | 20 (100%) |
| 50 | 20 (100%) | 20 (100%) |
| 65 | 20 (100%) | 20 (100%) |
| 75 | 19 (95%) | 19 (95%) |
| 85 | 15 (75%) | 15 (75%) |
Across all 136 studies, recruiting or not: 23% stop at 75 or younger and 20% at 65; 40% take children; 0% are for women only and 1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 50 of 136. Browse all 136 → or search them.
- CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill PatientsRecruitingNCT06811727Phase 41 country
- Early Optimization of Ceftazidime Regimen in Critical CareNot yet recruitingNCT07085624Not applicable1 country
- A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas AeruginosaNot yet recruitingNCT07804082Phase 31 country
- Microbiological Screening Of Malignant Otitis Externa Patients Presenting at Sohag University HospitalsRecruitingNCT077906791 country
- Remote Sputum Collection in Cystic FibrosisRecruitingNCT069508921 country
- MP101 in Adults With Acute Pseudomonas Aeruginosa PneumoniaRecruitingNCT07492771Phase 11 country
- First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected PatientsRecruitingNCT07708116Phase 11 country
- Ceftazidime-Avibactam PK/PD and Resistance in Hematology PatientsNot yet recruitingNCT077036441 country
- Further MT for Antibiotic-Resistant Bacterial ColonizationRecruitingNCT05835206Phase 21 country
- Antimicrobial Therapy for Difficult-to-treat Pseudomonas AeruginosaRecruitingNCT067387712 countries
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialRecruitingNCT06080698Not applicable1 country
- Pathobiomes in Gut of Critically Ill PatientsRecruitingNCT068224651 country
- Research on the Mechanism Affecting Progression of BronchiectasisRecruitingNCT057314271 country
- Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas AntibodiesRecruitingNCT043353831 country
- Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa InfectionNot yet recruitingNCT069865121 country
- Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas AeruginosaRecruitingNCT070568811 country
- Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)RecruitingNCT067602731 country
- Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University HospitalsRecruitingNCT064175931 country
- Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the PatientNot yet recruitingNCT06370299
- Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®RecruitingNCT06319235Phase 1/21 country
- Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa SepsisRecruitingNCT030442231 country
- Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas BacteremiaRecruitingNCT061131071 country
- Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder CancerRecruitingNCT05975151Phase 21 country
- Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and BronchiectasisNot yet recruitingNCT06035055Phase 4
- Clinical Outcomes in Patients With Infection by Resistant MicroorganismEnrolling by invitationNCT058800691 country
- Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas AeruginosaRecruitingNCT056427671 country
- Trikafta/Kaftrio and Pseudomonas AeruginosaRecruitingNCT056755921 country
- Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumoniaCompletedNCT03581370Phase 31 country
- Animal-Assisted Visitation Program Chlorhexidine TrialCompletedNCT04171817Phase 41 country
- PMT for MDRO DecolonizationCompletedNCT05632315Phase 21 country
- A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas AeruginosaCompletedNCT05453578Phase 1/21 country
- A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung InfectionCompletedNCT06016088Phase 1/22 countries
- Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas InfectionsCompletedNCT035103511 country
- Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in BronchiectasisCompletedNCT06093191Phase 41 country
- Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.CompletedNCT052820823 countries
- Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa BacteraemiaActive, not recruitingNCT05210439Phase 41 country
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell TransplantationTerminatedNCT04673175Phase 41 country
- Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionCompletedNCT05616221Phase 21 country
- Development and Validation of (Bio)Sensors for the Identification of PathogensCompletedNCT065488411 country
- Cystic Fibrosis Blood NeutrophilsCompletedNCT04970225Not applicable1 country
- Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. AeruginosaCompletedNCT03638830Phase 21 country
- Pentaglobin in CRE and PA Neutropenic InfectionsActive, not recruitingNCT03494959Phase 21 country
- Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis AirwaysCompletedNCT007000501 country
- RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot StudyCompletedNCT02295566Phase 21 country
- Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)CompletedNCT06141837
- Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli InfectionsTerminatedNCT05210387Not applicable1 country
- Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic FibrosisCompletedNCT04596319Phase 1/21 country
- CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)CompletedNCT04684641Phase 1/21 country
- FMT for MDRO Colonization After Infection in Renal Transplant RecipientsTerminatedNCT02922816Phase 11 country
- Targeted AntiBiotics for Chronic Pulmonary DiseasesTerminatedNCT03262142Phase 41 country